Search Abstracts

Background LA CAB/RPV has transformed the HIV treatment paradigm as an alternative to daily oral antiretroviral therapy (ART). Potential challenges with CAB/RPV include therapeutic failures characterized by virologic failure and/or the development of resistance-associated mutations (RAMs). Methods This was a single-center, retrospective cohort study of adults with HIV on LA CAB/RPV at the Ohio State…

Background The relevance of plasma (trough) concentrations of cabotegravir (CAB) and rilpivirine (RPV) with regard to sustained virologic suppression in people with HIV (PWH) on long-acting treatment (LA) is an ongoing matter of debate. We aimed to add to the currently available data by analyzing the association between CAB and RPV trough concentrations and viral…

Background The prevalence of obesity among women with HIV (WWH) is nearly 2-fold higher than in men with HIV, especially in sub-Saharan Africa. Obesity is closely associated with dysglycemia, and in the context of HIV frequently necessitates the co-administration of the first-line antiretroviral dolutegravir (DTG) and the insulin sensitizer metformin. However, a drug interaction exists…

Background Low plasma concentrations of LA CAB/RPV are associated with increased risk of virologic failure. However, trough LA CAB/RPV demonstrates high interindividual variability (CAB 31%, RPV 35%), and intraindividual variability (CAB 52%, RPV 29%) during the first 12 months of use. We sought to characterize the variability in trough plasma concentrations of CAB and RPV…

Background Approximately 58 million people are chronically infected with HCV globally, with approximately 1.5 million new infections per year and a disproportionate burden in low- and middle-income countries. Approved oral treatments, administered over 8 – 12 weeks, are highly effective demonstrating >98% sustained virological response (SVR) in RCTs. However, in some populations intention to treat…

Background In a Phase 2 study, oral once-weekly (QW) islatravir (ISL) plus lenacapavir (LEN) maintained high rates of viral suppression at 24 weeks in people with HIV-1 who were virologically suppressed (NCT05052996; Colson et al. CROI 2024; Abstract 208). To maintain high rates of viral suppression, it is important to ensure optimal drug concentrations in the…

Background Accessing feminizing hormone therapy (FHT) is essential to many trans women. Concern around drug-drug interactions between FHT and antiretroviral therapy (ART) can be a barrier to acceptance of ART for trans women with HIV. We measured serum estradiol concentrations in trans women with HIV taking FHT and BIC/FTC/TAF versus trans women without HIV taking…

Background Long acting injectable (LAI) antiretrovirals hold enormous potential for treatment and prevention of HIV in low- and middle-income countries (LMIC) but significant access challenges exist. One obstacle for generic LAIs is the assessment of “equivalence” with originator products. Accepted standards of bioequivalence for oral generic products may be sub-optimal because small differences may be…

Background Lenacapavir (LEN) is a potent first-in-class, long acting, capsid inhibitor recently approved for the treatment of multidrug-resistant HIV, in combination with other antiretroviral agents, in heavily treatment-experienced (HTE) people with HIV (PWH). PWH initiated usual or simplified regimen combining oral loading tablets and subcutaneous (SC) dose then SC maintenance dose (927 mg) every 6…

Background ACT (NCT05335590) is an ongoing observational study that aims to evaluate tenofovir-diphosphate (TFV-DP) concentrations in dried blood spots (DBS) among persons with HIV (PWH) receiving tenofovir alafenamide (TAF)-based antiretroviral therapy (ART) with suppressed compared with detectable HIV-1 RNA. Previously, QUANTI-TAF (NCT04065347) reported a pharmacokinetic (PK)-based TFV-DP in DBS benchmark of ≥1800 fmol/punches for PWH…